The novel Ebi3-IL-12alpha heterodimeric cytokine has been designated interleukin-35 (IL-35), is a member IL-12 family cytokine produced by regulatory T cells (Treg), but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of IL-12alpha (P35) and IL-27beta chains, which are encoded by two separate genes called IL-12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells, whereas recombinant IL-35 suppresses T-cell proliferation. It identify IL-35 as a novel inhibitory cytokine that may be specifically produced by T(reg) cells and is required for maximal suppressive activity. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells, suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4(+)CD25(+)Foxp3(+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation, another well-known anti-inflammatory cytokine, along with TGFbeta cytokine. IL-35 is a cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.
Immunogen Region
PRP100184
Tag
IL-35
Formulation
Lyophilized from sterile PBS, pH 7.4
Molecular Weight
73.4 kDa
Usage
Always centrifuge tubes before opening. It is recommended to reconstitute the lyophilized Human IL-35 (IL12A & IL27B) protein, Fc Tag in sterile ddH2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
Accession Number
NP_005746.2 & P29459
Precautions
The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Bioactivity
Measured by its ability to bind biotinylated human IL-6RB-Fch in a functional ELISA.
Protein Length
The recombinant human IL-35/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 645 amino acids and has a predicted molecular mass of 73.4 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhIL-35/Fc monomer is approximately 90-100 kDa due to glycosylation.
Others
The Endotoxin level is less than 1.0 EU per ug of the protein as determined by the LAL method Preparation Method: HEK293 Cells
Sequence
Amino acid sequence derived from human IL-35 complex composed of IL-27B subunit (NP_005746.2) (Met 1-Lys 229) and the mature form of human IL-12 p35 subunit (P29459) (Arg 23-Ser 219) linked by a polypeptide linker was fused with the Fc region of human IgG1 at the C-terminus.
Purity
> 85 % as determined by SDS-PAGE
Storage
Lyophilized Human IL-35 (IL-12A & IL-27B) protein, Fc Tagshould be stored desiccated below -20°C. Upon reconstitution, the protein should be stored at 4°C between 2-7 days and for future use below -20°C. For long term storage it is recommended to add a carrier protein (0.54% HSA or BSA). Please prevent freeze-thaw cycles.
Reviews of Human IL-35 (IL-12A & IL-27B) protein, Fc Tag